<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548921</url>
  </required_header>
  <id_info>
    <org_study_id>BioFridA 06-2020</org_study_id>
    <nct_id>NCT04548921</nct_id>
  </id_info>
  <brief_title>Biomarker for Friedreich's Ataxia (BioFridA)</brief_title>
  <acronym>BioFridA</acronym>
  <official_title>Biomarker for Friedreich's Ataxia: An International, Multicenter, Observational, Longitudinal Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CENTOGENE GmbH Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CENTOGENE GmbH Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, observational, longitudinal monitoring study to identify&#xD;
      biomarker/s for Friedreich's Ataxia and to explore the clinical robustness, specificity, and&#xD;
      long-term variability of these biomarker/s&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An ataxia is neurological disorder of balance and coordination resulting from dysfunctions of&#xD;
      the cerebellum. Friedreich's ataxia (FRDA) is most common ataxia in white population, with an&#xD;
      estimated prevalence of 2-4 cases per 100,000 individuals. With an average age of onset of&#xD;
      10-15 years, the disease is characterized by dysarthria, deep sensory loss, hypertrophic&#xD;
      cardiomyopathy, spinocerebellar ataxia, pyramidal weakness, diabetes mellitus, and skeletal&#xD;
      abnormalities.&#xD;
&#xD;
      FRDA is an autosomal recessive disorder caused by pathogenic variant/s in the FXN gene, which&#xD;
      encodes the mitochondrial protein frataxin. In 98% of cases these are homozygous&#xD;
      guanine-adenine-adenine (GAA) triplet repeat expansions in the ﬁrst intron of the FXN gene.&#xD;
      The remaining cases are compound heterozygotes for a GAA repeat expansion plus a FXN point&#xD;
      mutation or deletion. GAA repeat expansions suppress transcription of the FXN gene, leading&#xD;
      to frataxin deﬁciency.&#xD;
&#xD;
      Until now there is no FDA-approved therapy for FRDA, but potential agents for treatment are&#xD;
      in developing phases. As such, especially antioxidants like idebenone are tested in clinical&#xD;
      trials as FRTA medication, whereas another study identified p38 inhibitors as potential&#xD;
      therapeutic agents. Various clinical rating scales including the Scale for the Assessment and&#xD;
      Rating of Ataxia (SARA), Friedreich's Ataxia Rating Scale (FARS), and the International&#xD;
      Cooperative Ataxia Rating Scale (ICARS) have been used as trial endpoints in FRDA, but these&#xD;
      measurements have limited sensitivity to disease progression over 12 months. Furthermore,&#xD;
      there are no validated, objective central or peripheral nervous system biomarkers of disease&#xD;
      progression for use in clinical trials as intermediate endpoints.&#xD;
&#xD;
      It is the goal of the BioFridA study to identify, validate, and monitor FRDA biomarker/s.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of Friedreich's Ataxia biomarker/s</measure>
    <time_frame>36 months</time_frame>
    <description>All samples will be analyzed for the identification of potential biomarkers via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploring the clinical robustness, specificity, and long-term variability of Friedreich's Ataxia biomarker/s</measure>
    <time_frame>36 months</time_frame>
    <description>All samples will be analyzed for the identification of potential biomarkers via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>FXN Gene</condition>
  <condition>FRDA</condition>
  <condition>Hereditary Diseases</condition>
  <arm_group>
    <arm_group_label>Participants with Friedreich's Ataxia</arm_group_label>
    <description>Participant diagnosed with Friedreich's Ataxia aged between 2 and 50 years of age</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Friedreich's Ataxia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent is obtained from the participant or parent/ legal guardian&#xD;
&#xD;
          -  The participant is aged between 2 and 50 years of age&#xD;
&#xD;
          -  The diagnosis of Friedreich's Ataxia (FRDA) is genetically confirmed by CENTOGENE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Informed consent is not obtained from the participant and parent/ legal guardian&#xD;
&#xD;
          -  The participant is younger than 2 years or older than 50 years of age&#xD;
&#xD;
          -  The diagnosis of FRDA is not genetically confirmed by CENTOGENE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bauer, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>CENTOGENE GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saeedeh Ebadat, PhD</last_name>
    <phone>49 381 80113 400</phone>
    <email>saeedeh.ebadat@centogene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>American University of Science and Technology</name>
      <address>
        <city>Beirut</city>
        <zip>16-6452</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Megarbane, MD</last_name>
      <phone>+961 1421630</phone>
      <email>andre.megarbane@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Andre Megarbane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <link>
    <url>http://centogene.com</url>
    <description>CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Friedreich's Ataxia</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

